Live Radio
The Food and Drug Administration has authorized a second booster dose of the either the Moderna or Pfizer-BioNtech COVID-19 vaccine for older people and certain immunocompromised individuals. Emily Elconin/Getty Images hide caption
The Food and Drug Administration has authorized a second booster dose of the either the Moderna or Pfizer-BioNtech COVID-19 vaccine for older people and certain immunocompromised individuals.
Emily Elconin/Getty ImagesAn omicron subvariant known as BA.2 could soon become the dominant form of the coronavirus in the United States. It's not more deadly, but it is more transmissible.
At the same time, the Biden administration has authorized a second booster shot for people over 50 and other people vulnerable to infection.
But against that backdrop, Congress has so far refused to authorize more COVID spending measures, which would fund the stockpiling of more vaccine doses and public health surveillance for emerging variants.
NPR's Selena Simmons-Duffin reports on the funding debate. NPR's Michaeleen Doucleff looks at another variant whose creation gives scientists insight into how COVID-19 variants change, and why.
Email us at
This episode was produced by Brent Baughman. It was edited by Carrie Feibel, Vikki Valentine, Scott Hensley, and Ashley Brown. Our executive producer is Cara Tallo.
